Cent Eur J Public Health 2011, 19(3):128-130 | DOI: 10.21101/cejph.a3653

Prevalence of Human Leukocyte Antigen (HLA)-B*5701 in HIV-infected Subjects in Czech Republic

David Jilich1,2, Milena Vraná3, Svatava Snopková4, Dalibor Sedláček5, Jaroslav Kapla6, Hanuš Rozsypal1, Jitka Kolčáková6,2, Lenka Olbrechtová7, Alena Zjevíková7, Zdenka Jerhotová8, Marek Malý9, Marie Staňková1, Ladislav Machala10
1 Department of Infectious and Tropical Diseases, First Faculty of Medicine, Charles University in Prague, Czech Republic
2 University Hospital Bulovka, Prague, Czech Republic
3 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
4 Department of Infectious Diseases, University Hospital Brno, Czech Republic
5 Department of Infectious Diseases, Medical Faculty of Charles University and Faculty Hospital, Plzeň, Czech Republic
6 Department of Infectious Diseases, University Hospital Hradec Králové, Charles University, Hradec Králové, Czech Republic
7 Department of Infectious Diseases, Faculty Hospital Ostrava, Ostrava, Czech Republic
8 Department of Infectious Diseases, Hospital České Budějovice, České Budějovice, Czech Republic
9 Department of Biostatistics, National Institute of Public Health, Prague, Czech Republic
10 Department of Infectious Diseases, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

The HLA-B*57:01 allele is associated with a hypersensitivity reaction to abacavir, and its prevalence varies in different populations. The aim of the study was to investigate HLA-B*57:01 prevalence in the Czech HIV-infected population. HLA-B*57:01 prevalence in our cohort was 5.33%, which is similar to the situation in other Central European countries.

Keywords: abacavir, hypersensitivity, HLA-B*57:01, prevalence, Czech Republic

Received: November 19, 2010; Revised: May 25, 2011; Accepted: May 25, 2011; Published: September 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jilich D, Vraná M, Snopková S, Sedláček D, Kapla J, Rozsypal H, et al.. Prevalence of Human Leukocyte Antigen (HLA)-B*5701 in HIV-infected Subjects in Czech Republic. Cent Eur J Public Health. 2011;19(3):128-130. doi: 10.21101/cejph.a3653. PubMed PMID: 22026283.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hetherington S, McGuirk S, Powell G, CutrellA, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001 Oct;23(10):1603-14. Go to original source... Go to PubMed...
    2. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002 Mar 2;359(9308):727-32. Go to original source...
    3. Hetherington S, HughesAR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002 Mar 30;359(9312):1121-2. Go to original source... Go to PubMed...
    4. Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother. 2008 Mar;42(3):387-96. Go to original source... Go to PubMed...
    5. Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005 Jun 10;19(9):979-81. Go to original source... Go to PubMed...
    6. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 7;358(6):568-79. Go to original source... Go to PubMed...
    7. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004 Jun;14(6):335-42. Go to original source... Go to PubMed...
    8. Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W; Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008 Apr 1;46(7):1111-8. Go to original source... Go to PubMed...
    9. Allele Frequencies in Worldwide Populations [Internet]. Liverpool: The Allele Frequency net; 2011 [cited 2010 Nov 19]. Available from: http://www.allelefrequencies.net.
    10. Sun HY, Hung CC, Lin PH, Chang SF, Yang CY, Chang SY, et al. Incidence of abacavir hypersensitivity and its relationship with HLAB*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother. 2007 Sep;60(3):599-604. Go to original source... Go to PubMed...
    11. Zahlavova L, Bendukidze N, Ivaskova E. HLA-A, -B, -Cw, -DPB1, -DQA1, -DQB1 and -DRB1 allele frequencies in a population from the Czech Republic. Hum Immunol. 2004;65(9-10):925-30. Go to original source...
    12. Orkin C, Sadiq ST, Rice L, Jackson F; UK EPI team. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)B*5701 in HIV-1-infected UK subjects. HIV Med. 2010 Mar;11(3):18792. Go to original source... Go to PubMed...
    13. Tumanov A, Laga V, Kazennova O, et al. The prevalence of the HLAB*5701 allele in the European part of the Russian Federation.12th European AIDS Conference/EACS. HIV Med. 2009;10 (Suppl.2):84.
    14. Parczewski M, Leszczyszyn-Pynka M, WnukA, UrbañskaA, Fuksiñska K, Bander D, et al. Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients. HIV Med. 2010 May;11(5):345-8. Go to original source... Go to PubMed...

    Return to the content